US equities |
MU $991.64 ▼-3.63% META $749.26 ▲+4.26% NVDA $226.53 ▼-1.20% SNDK $1,481.09 ▼-6.37% SPCX $163.76 ▲+0.74% AMD $590.64 ▼-2.87% MSFT $540.62 ▲+1.04% TSLA $379.30 ▼-0.89%
FinancialContent

Regeneron Pharmaceuticals (NQ:REGN)

765.11 +18.57 (+2.49%)
Delayed Quote Updated: 1:51 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Discover which S&P500 stocks are making waves on Monday. ↗
Via Chartmill
News headline image
Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Regeneron (REGN) Stock Is Trading Lower Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology all... 
Via StockStory
Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount ↗
Via Chartmill
Which S&P500 stocks are moving on Thursday? ↗
Via Chartmill
News headline image
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,... 
Via MarketBeat
Topics ETFs
News headline image
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
News headline image
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30? ↗
The healthcare company will release its third-quarter results next month. 
Via The Motley Fool
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development... 
Via MarketBeat
Topics ETFs
News headline image
Is Regeneron Stock a Bargain Below $800? ↗
The past couple of years have been challenging for the company, but there is a light at the end of the tunnel. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock Worth Your Attention and 2 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global... 
Via MarketBeat
Topics Intellectual Property
News headline image
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo... 
Via MarketBeat
Topics ETFs
News headline image
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
From Pomerantz LLP
Via GlobeNewswire
News headline image
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that p... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >